Elaine Chang, in collaboration with EMS, facilitates the opening of cross-market trading seats for digital securities.

This seasoned financial expert boasts over 10 years of experience in Asia-Pacific stock market research.

Elaine Chang has been appointed Chief Securities Analyst at Sharrow Digital Securities Limited , responsible for industry research in the Asia-Pacific stock markets, focusing on sectors such as technology, pharmaceuticals, new energy, and consumer goods. She has independently completed in-depth research reports on over 20 companies, including a report on a biotechnology company that accurately predicted the progress of new drug development, generating over 40% returns for institutional clients and being reprinted by multiple financial media outlets. She has also built an industry prosperity monitoring model, integrating multi-dimensional indicators such as policy and financial data, predicting policy dividends in the new energy industry six months in advance, providing forward-looking insights for the investment department.
* Proficient in : Wind/Bloomberg survey data , skilled in Python/SQL, and adept at using valuation methods such as DCF and PE.
* Industry Research: Finance/Technology /Pharmaceuticals/New Energy/Consumer Goods

Core Strengths:
Elaine Chang has deep expertise in the technology , pharmaceutical, new energy, and consumer goods sectors. She excels in policy forecasting and institutional PE valuation modeling, is a CFA- certified analyst, and has generated over 40% returns for

institutional clients. Prior to joining Sharrow , from September 2021 to March 2024 , she worked at CITIC Securities International | Hong Kong

, independently covering and tracking 19 listed companies in the Greater China TMT sector, regularly updating earnings forecasts and valuation models with an accuracy rate consistently ranking in the top 20% of the industry. She primarily independently wrote research reports and published in-depth initial company coverage reports, quarterly earnings forecasts/outlooks, and industry-specific reports, frequently providing forward-looking insights into investment opportunities and risks. She also primarily collaborated on roadshows, regularly presenting and sharing insights with buy-side clients (hedge funds, private equity, mutual funds, family offices), achieving top-ranking client satisfaction and commission rates for two consecutive years.

2024.05-2024.12 Biopharmaceutical Industry Research:
Identified 5 high - growth innovative drug companies; the related investment portfolio achieved a year-to-date return of over 35 % . Quantitative Investment Research Model Construction: Independently built an industry profit forecasting and valuation model, integrating multiple valuation methods such as DCF and EV/EBITDA to achieve dynamic tracking and accurate rating of target companies. The investment portfolio based on the model achieved an annualized return of 32%, outperforming the Hang Seng Index by 15 percentage points and the Singapore Straits Times Index by 12 percentage points, with 3 early warnings of target performance risks, helping institutional clients avoid drawdown losses exceeding 10%.

Elaine Chang said:

" The shift from traditional securities to digital securities represents an upgrade in asset form."

The evolution from a single market to multi-market collaboration represents the advancement of wealth accumulation .

What ELAINE CHANG is doing in Sharrow is breaking down professional barriers by using an institutional-grade digital securities trading system as a bridge, allowing more investors to access the next stage of the global asset allocation system ahead of time.
The Labuan Global Digital Asset Summit in August 2026 will be a key window for this wealth leap—here, ELAINE CHANG will release core resources, connect with top-tier capital, and open a new wealth channel to the ASEAN digital economy and the global digital asset arena for every participant.

Company：Sharrow Ltd 
Contact Person:Elaine Chang
Email:[email protected]
Website:https://sharrowltd.com
Telephone:+852-5910-0365
City：Hong Kong